Published: 17 March 2026 | 5.40 AM
Last Updated: 17 March 2026 | 1.00 PM
IPO Overview / Intro
Speciality Medicines IPO is a book-built issue of Rs. 29.14 crores. The issue is entirely a fresh issue of 23.50 lakh shares.
👉 GMP | Reviews | Subscription | Allotment
Speciality Medicines IPO opens for subscription on Mar 20, 2026 and closes on Mar 24, 2026. The allotment for the IPO is expected to be finalised on Mar 25, 2026. The IPO will list on BSE SME with a tentative listing date of Mar 30, 2026.
Speciality Medicines IPO GMP – Latest Update
| GMP |
Trend |
Estimated Listing Price |
Expected Gain |
| 0 |
— |
Rs. 124 |
0% |
Speciality Medicines IPO Subscription Status – Live Update
IPO Details at a Glance
| Particulars |
Details |
| IPO Date |
20 to 24 Mar, 2026 |
| Listing Date |
Mar 30, 2026 |
| Face Value |
Rs. 10 per share |
| Price Band |
Rs. 117 to Rs. 124 |
| Lot Size |
1,000 Shares |
| Issue Type |
Book Built Issue |
| Total Issue Size |
23,50,000 shares (Rs. 29.14 Cr) |
| Fresh Issue |
23,50,000 shares |
| Market Maker Portion |
1,50,000 shares (Rs. 2 Cr) |
| Net Issue to Public |
22,00,000 shares (Rs. 27 Cr) |
| Listing At |
BSE SME |
| Shareholding Pre Issue |
64,35,796 shares |
| Shareholding Post Issue |
87,85,796 shares |
IPO Timetable
| Event |
Date |
| IPO Open |
Mar 20, 2026 |
| IPO Close |
Mar 24, 2026 |
| Allotment |
Mar 25, 2026 |
| Refund |
Mar 27, 2026 |
| Credit of Shares |
Mar 27, 2026 |
| Listing Date |
Mar 30, 2026 |
Reservation
| Investor Category |
Shares Offered |
| QIB |
Not more than 2% |
| Retail |
Not less than 49% |
| NII |
Not less than 49% |
Lot Size
| Application |
Lots |
Shares |
Amount |
| Retail (Min) |
2 |
2,000 |
Rs. 2,48,000 |
| Retail (Max) |
2 |
2,000 |
Rs. 2,48,000 |
| S-HNI (Min) |
3 |
3,000 |
Rs. 3,72,000 |
| S-HNI (Max) |
8 |
8,000 |
Rs. 9,92,000 |
| B-HNI (Min) |
9 |
9,000 |
Rs. 11,16,000 |
Company Details
Speciality Medicines Limited, incorporated in 2021, is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals, including high-cost oral and injectable medicines used to treat complex and chronic conditions across domestic and international markets.
The company offers a wide product portfolio across multiple dosage formats such as tablets, capsules, syrups, injections, inhalers, infusions, ophthalmic solutions and more.
It operates through two key models: contract manufacturing for global markets and marketing & distribution of sourced speciality pharmaceutical products.
The company has built a presence across more than 20 states in India and over 35 countries globally, including Jordan, Ethiopia, Uganda, Peru and Namibia.
Financials
| Period |
31 May 2024 |
31 Mar 2024 |
31 Mar 2023 |
31 Mar 2022 |
| Assets (Rs. Cr) |
26.44 |
23.43 |
13.26 |
5.78 |
| Revenue (Rs. Cr) |
8.37 |
27.66 |
23.26 |
40.45 |
| PAT (Rs. Cr) |
2.30 |
4.55 |
1.69 |
1.48 |
| Net Worth (Rs. Cr) |
19.23 |
16.61 |
5.87 |
1.93 |
| Reserves & Surplus (Rs. Cr) |
14.08 |
11.50 |
2.05 |
1.72 |
| Total Borrowing (Rs. Cr) |
2.53 |
2.86 |
3.64 |
1.18 |
Valuation
| Metric |
Value |
| EPS (Pre Issue) |
Rs. 7.06 |
| EPS (Post Issue) |
Rs. 15.79 |
| ROE |
40.44% |
| ROCE |
34.95% |
| RoNW |
27.36% |
| PAT Margin |
16.52% |
| Debt/Equity |
0.17 |
| Promoter Holding (Pre Issue) |
59.28% |
| Promoter Holding (Post Issue) |
43.44% |
Chanakya View
Speciality Medicines operates in the niche speciality pharma segment, which offers strong long-term growth potential driven by increasing demand for complex and chronic disease treatments.
The company has demonstrated strong profitability metrics with high ROE and ROCE along with a low debt profile, indicating efficient capital utilisation.
However, the company is relatively new with limited operating history and small scale, which raises concerns around sustainability and scalability of earnings.
Investors should track subscription demand and GMP trend closely. The issue may see interest due to strong margins, but listing gains could remain moderate.
Company Address
913, One World West, S. No. 396, FP 119,
Village Vejalpur, Ahmedabad, Gujarat – 380051
Email: investors.grievances@specialitymedicine.com
Phone: +91 22 4604 5344
Lead Manager & Registrar
| Particulars |
Details |
| Lead Manager |
Unicon Capital Services Pvt. Ltd. |
| Registrar |
Skyline Financial Services Pvt. Ltd. |
| Phone |
02228511022 |
| Email |
ipo@skylinerta.com |
